Cost-Effectiveness of Dolutegravir/Abacavir/Lamivudine in HIV-1 Treatment-Naive (TN) Patients in France - Sorbonne Université
Journal Articles Expert Review of Pharmacoeconomics & Outcomes Research Year : 2018

Cost-Effectiveness of Dolutegravir/Abacavir/Lamivudine in HIV-1 Treatment-Naive (TN) Patients in France

Domains

Human health and pathology

Gestionnaire HAL 3 Sorbonne Université  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03793518

Submitted on : Saturday, October 1, 2022-10:29:09 AM

Last modification on : Thursday, November 7, 2024-2:21:28 PM

No file

Dates and versions

hal-03793518 , version 1 (01-10-2022)

Identifiers

Cite

Gilles Pialoux, Anne-Geneviève Marcelin, Hélène Cawston, Caroline Guilmet, Laurent Finkielsztejn, et al.. Cost-Effectiveness of Dolutegravir/Abacavir/Lamivudine in HIV-1 Treatment-Naive (TN) Patients in France. Expert Review of Pharmacoeconomics & Outcomes Research, 2018, 18 (1), pp.83--91. ⟨10.1080/14737167.2017.1359542⟩. ⟨hal-03793518⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

IPLESP SORBONNE-UNIVERSITE SU-MEDECINE
27 View
0 Download

Altmetric

Share

More